Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
AVXL Anavex $2.31 0.115 (5.25%) 08:31 05/16/18 05/16 08:31 05/16/18 08:31 Initiation	Anavex initiated at Maxim » Anavex assumed with a Buy… Anavex assumed with a Buy at Maxim. Maxim analyst Caroline Palomeque assumed Anavex with a Buy rating and raised her price target to $7 from the prior $5. The analyst says she is factoring in additional revenue from further indications in Rett syndrome and Parkinson's disease on top of the company's Alzheimer's disease stream. with potential catalysts from the emerging data on the expanded 2-73 programs coming out in the second half of the year. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
AVXL Anavex $2.23 0.08 (3.72%) 07:13 04/17/18 04/17 07:13 04/17/18 07:13 Hot Stocks	Anavex to initiate ANAVEX2-73 Phase 2 study in PDD » Anavex Life Sciences… Anavex Life Sciences announced that the company is planning to initiate a Phase 2 clinical trial of lead candidate ANAVEX2-73 in Parkinson's Disease Dementia, or PDD. The company is moving forward with a Phase 2 trial with ANAVEX2-73 in PDD, which will study the effect of the compound on both the cognitive and motor impairment of Parkinson's disease. The double-blind, randomized, placebo-controlled Phase 2 PDD study has been submitted to regulatory authorities in Europe, and pending approval, the company plans to initiate this clinical trial H2 2018. Additional protocol details will be shared at that point. The earlier studies of ANAVEX2-73 in a disease modifying model of Parkinson's disease were funded by The Michael J. Fox Foundation for Parkinson's Research. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Apr
AVXL Anavex $2.89 -0.04 (-1.37%) 07:29 03/08/18 03/08 07:29 03/08/18 07:29 Initiation	Anavex initiated at Roth Capital » Anavex initiated with a… Anavex initiated with a Buy at Roth Capital. Roth Capital analyst Robert LeBoyer started Anavex with a Buy rating and $6 price target as the company plans to advance ANAVEX 2-73 to Phase 2b/3 clinical trials for Alzheimer's disease, a Phase 2 for Rett syndrome, and to file an IND to begin a Phase 2 study for Parkinson's disease. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Mar

Over a quarter ago
AVXL Anavex $2.85 0.05 (1.79%) 15:55 02/07/18 02/07 15:55 02/07/18 15:55 Conference/Events	Anavex to hold a conference call » Conference Call to… Conference Call to discuss earnings for the Q1, as well as provide a clinical update on the Company's most advanced clinical programs for ANAVEX(R)2-73, will be held on February 7 at 4:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Feb
AVXL Anavex $2.85 0.05 (1.79%) 09:14 02/07/18 02/07 09:14 02/07/18 09:14 Conference/Events	Anavex to hold a conference call » Conference Call to… Conference Call to discuss earnings for the Q1, as well as provide a clinical update on the Company's most advanced clinical programs for ANAVEX(R)2-73, will be held on February 7 at 4:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Feb

FSNN Fusion Telecommunications $3.59 -0.06 (-1.64%) , GLDD Great Lakes Dredge $4.95 0.05 (1.02%) … 08:55 01/29/18 01/29 08:55 01/29/18 08:55 Conference/Events	Noble Capital Markets to hold a conference » 14th Annual Institutional… 14th Annual Institutional Investor Conference is being held in Fort Lauderdale, FL on January 29-30 with webcasted company presentations to begin on January 29 at 9 am; not all company presentations may be webcasted. Webcast Link FSNN Fusion Telecommunications $3.59 -0.06 (-1.64%) GLDD Great Lakes Dredge $4.95 0.05 (1.02%) MNKD MannKind $2.79 -1.01 (-26.58%) EVC Entravision $7.40 0.1 (1.37%) KEYW KEYW TESS TESSCO $22.45 0.25 (1.13%) MGRC McGrath RentCorp $49.40 0.77 (1.58%) SEAC SeaChange $3.37 0.01 (0.30%) STNG Scorpio Tankers $2.85 -0.13 (-4.36%) CLRB Cellectar Biosciences $1.23 0.04 (3.36%) VTGN VistaGen Therapeutics $1.59 -0.08 (-4.79%) DYAI Dyadic International IDXG Interpace Diagnostics $1.13 0.04 (3.67%) BTX BioTime $2.89 0.15 (5.47%) CVU CPI Aerostructures $9.15 -0.021 (-0.23%) GNE Genie Energy $4.42 0.01 (0.23%) PANL Pangaea Logistics $2.50 -0.11 (-4.21%) BSET Bassett Furniture $35.80 0.25 (0.70%) AVXL Anavex $3.02 -0.04 (-1.31%) FISH Now trades under AZUR RMR RMR Group $65.40 -0.85 (-1.28%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	29 Jan 07 Feb 21 Feb 22 Feb 27 Feb 01 Mar 14 Jun
FSNN Fusion Telecommunications $3.59 -0.06 (-1.64%) , GLDD Great Lakes Dredge $4.95 0.05 (1.02%) … 07:16 01/29/18 01/29 07:16 01/29/18 07:16 Conference/Events	Noble Capital Markets to hold a conference » 14th Annual Institutional… 14th Annual Institutional Investor Conference is being held in Fort Lauderdale, FL on January 29-30 with webcasted company presentations to begin on January 29 at 9 am; not all company presentations may be webcasted. Webcast Link FSNN Fusion Telecommunications $3.59 -0.06 (-1.64%) GLDD Great Lakes Dredge $4.95 0.05 (1.02%) MNKD MannKind $2.79 -1.01 (-26.58%) EVC Entravision $7.40 0.1 (1.37%) KEYW KEYW TESS TESSCO $22.45 0.25 (1.13%) MGRC McGrath RentCorp $49.40 0.77 (1.58%) SEAC SeaChange $3.37 0.01 (0.30%) STNG Scorpio Tankers $2.85 -0.13 (-4.36%) CLRB Cellectar Biosciences $1.23 0.04 (3.36%) VTGN VistaGen Therapeutics $1.59 -0.08 (-4.79%) DYAI Dyadic International IDXG Interpace Diagnostics $1.13 0.04 (3.67%) BTX BioTime $2.89 0.15 (5.47%) CVU CPI Aerostructures $9.15 -0.021 (-0.23%) GNE Genie Energy $4.42 0.01 (0.23%) PANL Pangaea Logistics $2.50 -0.11 (-4.21%) BSET Bassett Furniture $35.80 0.25 (0.70%) AVXL Anavex $3.02 -0.04 (-1.31%) FISH Now trades under AZUR RMR RMR Group $65.40 -0.85 (-1.28%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	29 Jan 07 Feb 21 Feb 22 Feb 27 Feb 01 Mar 14 Jun
AVXL Anavex $3.40 -0.03 (-0.87%) 07:09 01/16/18 01/16 07:09 01/16/18 07:09 Hot Stocks	Anavex reports potential normalization of hypertension with ANAVEX2-73 published » Anavex Life Sciences… Anavex Life Sciences reports that the peer-reviewed scientific journal The Journal of Clinical Hypertension has published a post-hoc analysis of blood pressure data collected during the Phase 2a study in mild-to-moderate Alzheimer's disease patients demonstrating that ANAVEX2-73 seems to normalize systolic blood pressure, or SBP, in a patient population with risk for hypertension. Statistical analyses including paired t-testing and multivariable linear mixed effects modeling indicate a normalization of SBP from the first reading of 143.3 mmHg to the subsequent readings after ANAVEX2-73 administration of 132.5 mmHg at day 25 and of 135.3 mmHg at day 36, respectively. High blood pressure, or hypertension, occurs when either systolic or diastolic pressure remains elevated over time. High blood pressure is dangerous because it makes the heart work too hard and its extra force can damage arteries. Uncontrolled high blood pressure can lead to heart disease, kidney damage or stroke. New evidence also links high blood pressure to increased risk of cognitive decline and dementia. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AVXL Anavex $3.69 0.08 (2.22%) 15:55 12/11/17 12/11 15:55 12/11/17 15:55 Conference/Events	Anavex to hold a conference call » Management discusses… Management discusses financial results for fiscal year ended September 30, 2017, as well as provides an update on ANAVEX 2-73 for treatment of Rett syndrome (RTT) on a conference call to be held on December 11 at 4:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	11 Dec
AVXL Anavex $3.69 0.08 (2.22%) 09:16 12/11/17 12/11 09:16 12/11/17 09:16 Conference/Events	Anavex to hold a conference call » Management discusses… Management discusses financial results for fiscal year ended September 30, 2017, as well as provides an update on ANAVEX 2-73 for treatment of Rett syndrome (RTT) on a conference call to be held on December 11 at 4:30 pm. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

On The Fly

News and insights, exclusive to thefly.com

13:15	Notable companies reporting before tomorrow's open»
13:15	Notable companies reporting after market close»
12:09	On The Fly: Top stock stories at midday»
10:43	On The Fly: Top five analyst initiations»
10:43	On The Fly: Top five analyst downgrades»

View all On The Fly Stories »

Upcoming
Events (10)

Today		Automotive Aftermarket Investor Conference
Today	NTWK ...	19th Annual Investor Conference
Today	MPLX ...	MLP & Energy Infrastructure Conference
Today		10th DIA China Annual Meeting
Today		Summit on Healthcare Costs in America 2018
Today	NBL ...	Global Oil & Gas Conference
Today		3rd Annual Technology Conference: Pure/Accelerate 2018
Today		Nordic Large Cap Investor Day
Today		2018 Biotech West Coast Bus Tour
Today		Future Metals Corporate Day

View all of today’s events »

Today’s
Syndicate (12)

CLPS	IPO
GSKY	IPO
KNSA	IPO
SRRK	IPO
MLNT	Secondary
RP	Secondary
SAIL	Secondary
AGNC	Spot Secondary
EIGR	Spot Secondary
FND	Spot Secondary
GNBC	Spot Secondary
QUIK	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial